• About Us
  • Board of Advisors
  • Contact

MALARIA.com

A Malaria Information and Community Portal

  • Home
  • Malaria Overview
  • Malaria Research
  • News
  • Videos
  • Blogs
  • Malaria Q&A
  • Events
  • Jobs
Home / Malaria News / Pharma Service Company Quintiles Selected for Gates Foundation Consortium Clinical Trials Work

Pharma Service Company Quintiles Selected for Gates Foundation Consortium Clinical Trials Work

March 27, 2011 By Malaria.com Leave a Comment

Quintiles,an integrated biopharmaceutical company, has been named a preferred provider to a consortium of 14 global health Product Development Partnerships (PDPs), funded in part by the Bill and Melina Gates Foundation . PDPs are not-for-profit entities formed for the purpose of advancing global health and the health of the world’s poorest by the discovery, development and delivery of new effective and affordable medicines for the most neglected diseases in the world.

The 14 PDPs anticipate funding 128 phase I-IV clinical trials over the next two years 2011-2013. The Bill and Melinda Gates Foundation has committed $10 billion over the next 10 years to help research, develop and deliver vaccines and treatments for the world’s poorest countries, with a portion of that commitment directed to the PDPs. The PDPs also receive funding from government agencies, private entities and other sources.

Quintiles will partner with the consortium members by providing one-step access to Quintiles’ global clinical development infrastructure and standards, particularly in the area of infectious diseases such as HIV, malaria and tuberculosis.

“Quintiles is extremely pleased to have been chosen by the consortium members,” said Dr. Kelly McKee, M.D., Quintiles Vice President and Managing Director, Public Health and Government Services. “The work they’re doing has the potential to reshape global health within a generation. The public health issues on which they are focused has the potential to save millions of lives. We are very excited to be named a preferred provider to the consortium and look forward to helping advance this critical mission.”

Source: Business Wire

Filed Under: Malaria News Tagged With: Gates Foundation, HIV, Product Development Partnerships, Quintiles, TB, Tuberculosis

Leave a Reply Cancel reply

You must be logged in to post a comment.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Stay Informed

WWARN Corner

About WWARN

The WorldWide Antimalarial Resistance Network (WWARN) generates innovative resources and reliable evidence to inform the malaria community on the factors affecting the efficacy of antimalarial medicines. Learn more…

  • Fighting Malaria Requires Protecting the Effectiveness of Antimalarial Medicines
  • Data Sharing at IDDO
  • Evidence to inform equitable dosing in very young and malnourished children

More WWARN Stories...

  • Home
  • Malaria Overview
  • Malaria Research
  • News
  • Videos
  • Blogs
  • Malaria Q&A
  • Events
  • Jobs
  • About Us
  • Board of Advisors
  • Contact

Copyright © 2025 Malaria.com · Log in